BR112021014102A2 - Moléculas de ligação a lilrb3 e usos das mesmas - Google Patents
Moléculas de ligação a lilrb3 e usos das mesmas Download PDFInfo
- Publication number
- BR112021014102A2 BR112021014102A2 BR112021014102-2A BR112021014102A BR112021014102A2 BR 112021014102 A2 BR112021014102 A2 BR 112021014102A2 BR 112021014102 A BR112021014102 A BR 112021014102A BR 112021014102 A2 BR112021014102 A2 BR 112021014102A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794064P | 2019-01-18 | 2019-01-18 | |
| US62/794,064 | 2019-01-18 | ||
| PCT/CA2020/050042 WO2020146946A1 (en) | 2019-01-18 | 2020-01-16 | Lilrb3-binding molecules and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021014102A2 true BR112021014102A2 (pt) | 2021-09-21 |
Family
ID=71612981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021014102-2A BR112021014102A2 (pt) | 2019-01-18 | 2020-01-16 | Moléculas de ligação a lilrb3 e usos das mesmas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12404327B2 (https=) |
| EP (1) | EP3911680A4 (https=) |
| JP (1) | JP7631203B2 (https=) |
| KR (1) | KR20210118116A (https=) |
| CN (1) | CN113454123A (https=) |
| AU (1) | AU2020209367A1 (https=) |
| BR (1) | BR112021014102A2 (https=) |
| CA (1) | CA3126295A1 (https=) |
| EA (1) | EA202192008A1 (https=) |
| IL (1) | IL284781A (https=) |
| MX (1) | MX2021008507A (https=) |
| SG (1) | SG11202107663UA (https=) |
| TW (1) | TWI852980B (https=) |
| WO (1) | WO2020146946A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7181438B2 (ja) * | 2019-08-06 | 2022-11-30 | アプリノイア セラピューティクス リミテッド | 病理学的タウ種に結合する抗体及びその使用 |
| EP4255451A4 (en) * | 2020-12-03 | 2025-01-01 | The Board Of Regents Of The University Of Texas System | Methods for identifying lilrb-blocking antibodies |
| CN115925941B (zh) * | 2022-06-08 | 2026-04-03 | 北京科诺信诚科技有限公司 | 靶向人lilrb4的纳米抗体及其应用 |
| WO2025231127A1 (en) * | 2024-05-02 | 2025-11-06 | The Regents Of The University Of California | Compositions and methods for intracellular antigen targeting with antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| WO2011091181A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| CA2787783A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
| CA2867444C (en) | 2012-03-16 | 2021-04-13 | University Health Network | Compositions containing soluble toso protein and uses thereof |
| US20150174203A1 (en) | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
| US9493561B2 (en) | 2013-07-03 | 2016-11-15 | University Health Network | Antibodies to Toso |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| US20180201676A1 (en) | 2015-02-11 | 2018-07-19 | University Health Network | Methods and compositions for modulating lilr proteins |
| US10882905B2 (en) | 2015-03-05 | 2021-01-05 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases |
| CA2977544C (en) | 2015-03-06 | 2023-12-19 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| WO2018119425A2 (en) * | 2016-12-22 | 2018-06-28 | Icahn School Of Medicine At Mount Sinai | Anti-lilrb3 antibodies and methods of use thereof |
-
2020
- 2020-01-16 CA CA3126295A patent/CA3126295A1/en active Pending
- 2020-01-16 WO PCT/CA2020/050042 patent/WO2020146946A1/en not_active Ceased
- 2020-01-16 JP JP2021541292A patent/JP7631203B2/ja active Active
- 2020-01-16 CN CN202080015060.4A patent/CN113454123A/zh active Pending
- 2020-01-16 TW TW109101527A patent/TWI852980B/zh active
- 2020-01-16 SG SG11202107663UA patent/SG11202107663UA/en unknown
- 2020-01-16 KR KR1020217026164A patent/KR20210118116A/ko not_active Ceased
- 2020-01-16 EA EA202192008A patent/EA202192008A1/ru unknown
- 2020-01-16 BR BR112021014102-2A patent/BR112021014102A2/pt unknown
- 2020-01-16 AU AU2020209367A patent/AU2020209367A1/en active Pending
- 2020-01-16 US US17/421,705 patent/US12404327B2/en active Active
- 2020-01-16 EP EP20741290.9A patent/EP3911680A4/en active Pending
- 2020-01-16 MX MX2021008507A patent/MX2021008507A/es unknown
-
2021
- 2021-07-12 IL IL284781A patent/IL284781A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210118116A (ko) | 2021-09-29 |
| IL284781A (en) | 2021-08-31 |
| US12404327B2 (en) | 2025-09-02 |
| WO2020146946A1 (en) | 2020-07-23 |
| CA3126295A1 (en) | 2020-07-23 |
| US20220089723A1 (en) | 2022-03-24 |
| MX2021008507A (es) | 2021-09-21 |
| JP7631203B2 (ja) | 2025-02-18 |
| TWI852980B (zh) | 2024-08-21 |
| EA202192008A1 (ru) | 2021-10-21 |
| EP3911680A1 (en) | 2021-11-24 |
| JP2022517809A (ja) | 2022-03-10 |
| EP3911680A4 (en) | 2022-09-07 |
| SG11202107663UA (en) | 2021-08-30 |
| TW202031685A (zh) | 2020-09-01 |
| CN113454123A (zh) | 2021-09-28 |
| AU2020209367A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7596298B2 (ja) | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 | |
| US12404327B2 (en) | LILRB3-binding molecules and uses therefor | |
| US20240150462A1 (en) | Lilrb1 and lilrb2-binding molecules and uses therefor | |
| US20220153834A1 (en) | Tsg-6 antibodies and uses therefor | |
| US12286476B2 (en) | FCMR-binding molecules and uses thereof | |
| EA046937B1 (ru) | Lilrb3-связывающие молекулы и варианты их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023000904-5 PROTOCOLO 870230004604 EM 17/01/2023 15:48. |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |